WEGOVY 0.5MG INJECTION – Semaglutide 0.5mg

WEGOVY 0.5MG INJECTION contains Semaglutide 0.5mg, a GLP-1 receptor agonist used for chronic weight management in eligible adults and adolescents according to applicable prescribing information.

Semaglutide mimics the activity of the naturally occurring hormone GLP-1. It acts on GLP-1 receptors involved in appetite and energy regulation, helping reduce food intake and increase feelings of fullness. When combined with a reduced-calorie diet and increased physical activity, these effects can contribute to weight reduction.

WEGOVY 0.5MG is not the initial dose. Treatment generally begins with 0.25mg once weekly for the first four weeks, followed by 0.5mg once weekly. Further dose escalation is performed according to the prescribing instructions and individual tolerability.

Key Product Information

How Wegovy Works

Semaglutide activates GLP-1 receptors, which can:

• Reduce appetite
• Reduce food intake
• Increase feelings of fullness
• Influence energy intake and body weight

Wegovy is intended to be used alongside appropriate dietary and physical-activity measures.

Dosage & Dose Escalation

The usual Wegovy dose-escalation schedule is:

Dose escalation is intended to improve gastrointestinal tolerability. If significant gastrointestinal symptoms occur, escalation may be delayed according to the prescribing information.

How to Use

• Inject once weekly.
• Administer subcutaneously in the abdomen, thigh, or upper arm.
• It may generally be administered at any time of day, with or without meals.
• Try to use it on the same day each week.
• Rotate injection sites.
• Do not administer intravenously or intramuscularly.
• Follow the instructions supplied with the specific Wegovy injection device.